Effect of protracted treatment with rosiglitazone, a PPARγ agonist, in patients with Cushing's disease

Clinical Endocrinology

Volumn 64, Issue 2, 2006, Pages 219-224

  Giraldi, Francesca Pecori ^a   Scaroni, Carla ^b   Arvat, Emanuela ^c   De Martin, Martina ^a   Giordano, Roberta ^c   Albiger, Nora ^b   Leao, Adriana A S ^a   Picu, Andreea ^c   Mantero, Franco ^b   Cavagnini, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOTROPIN BLOOD LEVEL; CUSHING DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFECT; ECCHYMOSIS; EDEMA; FEMALE; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN SENSITIVITY; MALE; OSCILLATION; PARAMETER; PATIENT; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

ADRENOCORTICOTROPIC HORMONE; ADULT; BLOOD GLUCOSE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYDROCORTISONE; INSULIN RESISTANCE; MALE; MIDDLE AGED; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PITUITARY ACTH HYPERSECRETION; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 33645025854     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02452.x     Document Type: Article

References (18)

1. Miller J.W. Crapo L. 1993 The medical treatment of Cushing's syndrome Endocrine Reviews 14 443 458
2. Heaney A.P. Manory F. Hong W.H. Melmed S. 2002 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas Nature Medicine 8 1281 1287
3. Koeffler H.P. 2003 Peroxisome proliferator-activated receptor gamma and cancers Clinical Cancer Research 9 1 9
4. Heaney A.P. Drange M.R. Melmed S. 2003 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (Cushing's disease) 85th Annual Meeting of the Endocrine Society OR7 4 Philadelphia, PA, USA
5. Ambrosi B. Dall'Asta C. Cannavò S. Libè R. Vigo T. Epaminonda P. Chiodini I. Ferrero S. Trimarchi F. Arosio M. Beck-Peccoz P. 2004 Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease European Journal of Endocrinology 151 173 178
6. Suri D. Weiss R.E. 2005 Effect of pioglitazone on ACTH and cortisol secretion in Cushing's disease Journal of Clinical Endocrinology and Metabolism 90 1340 1346
7. Cannavò S. Arosio M. Almoto B. Dall'Asta C. Ambrosi B. 2005 Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease Clinical Endocrinology 63 118 119
8. Invitti C. Pecori Giraldi F. De Martin M. Cavagnini F. & the Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis 1999 Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study Journal of Clinical Endocrinology and Metabolism 84 440 448
9. Páez Pereda M. Kovalovsky D. Hopfner U. Theodoropoulou M. Pagotto U. Uhl E. Losa M. Stalla J. Grübler Y. Missale C. Arzt E. Stalla G.K. 2001 Retinoic acid prevents experimental Cushing's syndrome Journal of Clinical Investigation 108 1123 1131
10. Hull S.S.A. Sheridan B. Atkinson A.B. 2005 Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome Clinical Endocrinology 62 259 261
11. Patel J. Anderson R.J. Rappaport E.B. 1999 Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study Diabetes, Obesity and Metabolism 1 166 172
12. Losa M. Barzaghi R. Mortini P. Franzin A. Mangili F. Terreni M.R. Giovanelli M. 2000 Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas American Journal of Pathology 156 245 251
13. Jaffrain-Rea M.L. Di Stefano D. Minniti G. Esposito V. Bultrini A. Ferretti E. Santoro A. Faticanti Scucchi L. Gulino A. Cantore G. 2002 Cushing's disease: a comparison of pituitary corticotroph microadenomas and macroadenomas Endocrine-Related Cancer 9 103 113
14. Betz M.J. Shapiro I. Fassnacht M. Hahner S. Reincke M. Beuschlein F. 2005 Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation Journal of Clinical Endocrinology and Metabolism 90 3886 3896
15. Arlt W. Auchus R.J. Miller W.L. 2001 Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase Journal of Biological Chemistry 276 16767 16771
16. Azziz R. Ehrmann D.A. Legro R.S. Fereshetian A.G. O'Keefe M. Ghazzi M.N. 2003 Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome Fertility and Sterility 79 932 937
17. Bogazzi F. Ultimieri F. Raggi F. Russo D. Vanacore R. Guida C. Viacava P. Cecchetti D. Acerbi G. Brogioni S. Cosci C. Gasperi M. Bartalena L. Martino E. 2004 PPAR-gamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas European Journal of Endocrinology 150 863 875
18. Heaney A.P. Fernando M. Melmed S. 2003 PPAR-γ receptor ligands: novel therapy for pituitary adenomas Journal of Clinical Investigation 111 1381 1388